Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1638

1.

Management of Psychosis and Agitation in Medical-Surgical Patients Who Have or Are at Risk for Prolonged QT Interval.

Ries R, Sayadipour A.

J Psychiatr Pract. 2014 Sep;20(5):338-44. doi: 10.1097/01.pra.0000454778.29433.7c.

PMID:
25226194
[PubMed - in process]
2.

The psychopharmacology algorithm project at the harvard South shore program: an algorithm for acute mania.

Mohammad O, Osser DN.

Harv Rev Psychiatry. 2014 Sep-Oct;22(5):274-94. doi: 10.1097/HRP.0000000000000018.

PMID:
25188733
[PubMed - in process]
3.

QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review.

Hasnain M, Vieweg WV.

CNS Drugs. 2014 Aug 29. [Epub ahead of print]

PMID:
25168784
[PubMed - as supplied by publisher]
4.

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis.

Pérez-Iglesias R, Ortiz-Garcia de la Foz V, Martínez García O, Amado JA, Garcia-Unzueta MT, Ayesa-Arriola R, Suarez-Pinilla P, Tabares-Seisdedos R, Crespo-Facorro B.

Schizophr Res. 2014 Aug 20. pii: S0920-9964(14)00402-2. doi: 10.1016/j.schres.2014.07.045. [Epub ahead of print]

PMID:
25151200
[PubMed - as supplied by publisher]
5.

Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect.

Miao Y, Chen G, Ren L, Pingkai O.

Drug Deliv. 2014 Aug 22:1-10. [Epub ahead of print]

PMID:
25148542
[PubMed - as supplied by publisher]
6.

Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state.

Yanfei M, Guoguang C, Lili R, Pingkai O.

Drug Dev Ind Pharm. 2014 Aug 20:1-10. [Epub ahead of print]

PMID:
25138348
[PubMed - as supplied by publisher]
7.

Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders.

Partyka A, Jarosz J, Wasik A, Jastrzębska-Więsek M, Zagórska A, Pawłowski M, Wesołowska A.

J Pharm Pharmacol. 2014 Aug 13. doi: 10.1111/jphp.12305. [Epub ahead of print]

PMID:
25131522
[PubMed - as supplied by publisher]
8.

Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST.

Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J; EUFEST Study Group.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1500-5. doi: 10.1016/j.euroneuro.2014.07.001. Epub 2014 Jul 21.

PMID:
25085534
[PubMed - in process]
9.

Polyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone.

Dietrich-Muszalska A, Kopka J, Kontek B.

Schizophr Res Treatment. 2014;2014:602390. doi: 10.1155/2014/602390. Epub 2014 Jun 25.

PMID:
25061527
[PubMed]
Free PMC Article
10.

Treatment with Ziprasidone for schizophrenia patients with OCD.

Juven-Wetzler A, Fostick L, Cwikel-Hamzany S, Balaban E, Zohar J.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1454-62. doi: 10.1016/j.euroneuro.2014.06.014. Epub 2014 Jul 4.

PMID:
25048540
[PubMed - in process]
11.

Evaluation of the Potential for a Pharmacokinetic Drug-Drug Interaction Between Armodafinil and Ziprasidone in Healthy Adults.

Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P Jr.

Clin Drug Investig. 2014 Jul 22. [Epub ahead of print]

PMID:
25047407
[PubMed - as supplied by publisher]
12.

Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients.

Mercolini L, Mandrioli R, Protti M, Conca A, Albers LJ, Raggi MA.

Bioanalysis. 2014 Jun;6(11):1487-95. doi: 10.4155/bio.14.3.

PMID:
25046049
[PubMed - in process]
13.

[Antipsychotic drugs and their influence on the carbohydrate metabolism in patients with schizophrenia-spectrum disorders].

[No authors listed]

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):86-91. Russian.

PMID:
25035885
[PubMed - in process]
14.

The Role of Atypical Antipsychotics for Treatment of Tourette's Syndrome: An Overview.

Budman CL.

Drugs. 2014 Jul;74(11):1177-93. doi: 10.1007/s40265-014-0254-0.

PMID:
25034359
[PubMed - in process]
15.

Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro.

Sárvári AK, Veréb Z, Uray IP, Fésüs L, Balajthy Z.

Biochem Biophys Res Commun. 2014 Aug 8;450(4):1383-9. doi: 10.1016/j.bbrc.2014.07.005. Epub 2014 Jul 11.

PMID:
25019983
[PubMed - in process]
16.

Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder: Does quetiapine holds the solution?

Tripathi P, Agrawal H, Goyal P, Kar SK.

Ind Psychiatry J. 2013 Jul;22(2):159-60. doi: 10.4103/0972-6748.132934.

PMID:
25013321
[PubMed]
Free PMC Article
17.

Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.

Bartolommei N, Casamassima F, Pensabene L, Luchini F, Benvenuti A, Di Paolo A, Cosentino L, Mauri M, Lattanzi L.

ISRN Psychiatry. 2014 Apr 7;2014:904829. doi: 10.1155/2014/904829. eCollection 2014.

PMID:
25006524
[PubMed]
Free PMC Article
18.

Current status of atypical antipsychotics for the treatment of fibromyalgia.

Rico-Villademoros F, Calandre EP, Slim M.

Drugs Today (Barc). 2014 Jun;50(6):435-44. doi: 10.1358/dot.2014.50.6.2127023.

PMID:
24983591
[PubMed - in process]
19.

Safety of antipsychotic drugs: focus on therapeutic and adverse effects.

Werner FM, Coveñas R.

Expert Opin Drug Saf. 2014 Aug;13(8):1031-42. doi: 10.1517/14740338.2014.935761. Epub 2014 Jun 30.

PMID:
24975932
[PubMed - in process]
20.

Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.

Park T, Kuntz KM.

Value Health. 2014 Jun;17(4):310-9. doi: 10.1016/j.jval.2014.02.008. Epub 2014 May 10.

PMID:
24968989
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk